Compare Abbott Laboratories (ABT) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs NetEase Inc — how do they compare? Abbott Laboratories trades at $111 (market cap $187.95B), while NetEase Inc trades at $124.26 (market cap $82.75B). The key difference: Abbott Laboratories is far larger — about 2.3× NetEase Inc's market cap, and NetEase Inc pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| ABT | NTES | |
|---|---|---|
Market Cap | $187.95B | $82.75B |
Sector | Health | Media |
52-Week High | $136.62 | $159.34 |
52-Week Low | $82.57 | $109.26 |
Enterprise Value | $214.96B | $59.05B |
Dividend Yield | 2.32% | 2.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
NetEase (NTES) trades at $124.26, down 6.86% over 24 hours, with a P/E of 16.31 and P/S of 4.86. Recent earnings show a beat in Q1 2026 but misses in prior quarters. The company maintains strong profitability with a net income margin of 29.84% and ROE of 22.12%. Technical indicators signal a bullish trend, supported by positive analyst sentiment with 82% buy ratings.
The outlook for NTES is positive due to robust fundamentals and international expansion potential. Risks include earnings volatility and competitive pressures in the gaming sector. Upside is supported by a $0.72 dividend and strong cash flow generation, though investors should monitor quarterly performance against expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
